Enabling patients with autoimmune diseases to reimagine life. Backed by NEA and Norwest.
About the role
Zenas BioPharma is seeking an experienced Associate Director, New Product Planning & Competitive Intelligence to proactively support and advance the company’s New Product Planning and Competitive Intelligence activities. Reporting to the Vice President of Corporate Development and New Product Planning, this individual will play a critical role in advancing Zenas BioPharma’s ambition to build a robust and differentiated I&I portfolio.
What they're looking for
- Bachelor's degree in a life sciences, business, or related discipline required, advanced degree (PhD, PharmD, MD, MS, or MBA) preferred
- 6+ years of relevant experience in pharmaceutical/biotech competitive intelligence, strategy, consulting, equity research, or a closely related field
- Proficient in the use of CI tools to support data-driven decision making
- Experience managing CI vendors or external partners with an emphasis on quality, timeliness, and alignment to strategic goals
- Able to synthesize primary and secondary CI and translate findings into clear, actionable implications
- Strong collaboration, communication, and presentation skills, with the ability to influence across functions and organizational levels
More about this role
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase...
Browse similar: Startup jobs